New acid reducer shows promise in fighting stomach bug
NCT ID NCT07606833
First seen Jun 01, 2026 · Last updated Jun 23, 2026 · Updated 7 times
Summary
This Phase 3 trial tests whether a new acid-reducing drug, anaprazole, works better than the standard drug esomeprazole when used with bismuth and two antibiotics to treat H. pylori infection. About 556 adults in China will take either anaprazole or esomeprazole pills twice daily for 14 days. The main goal is to see if the infection is gone after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Hospital of Southern Medical University
Shenzhen, Guangdong, 518100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anaprazole sodium (a drug that reduces stomach acid) combined with bismuth, amoxicillin, and clarithromycin
What this could lead to
If successful, this could provide a new treatment option for H. pylori infection, potentially improving eradication rates.
What could go wrong
This is a Phase 3 trial, but results may not apply to all populations. The treatment includes antibiotics, which can cause side effects like diarrhea or allergic reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.